The Entrepreneurship of Psychedelic Negativity: Psymposia, Trauma, Iatrogenic Harm, and Prohibition 2.0
Contemporary Drug Problems July 10, 2026 Peer reviewed DOI: 10.1177/00914509261466701 via OpenAlex
Summary
A skeptical analysis of Psymposia, a U.S.-based psychedelics watchdog group, argues that its campaign against MDMA-assisted therapy for PTSD—including its "Power Trip" podcast, FDA hearing interventions, and allegations of a "Psychedelic Syndicate"—constituted an effective entrepreneurship of psychedelic negativity. The group employed sensationalism and a narrow definition of iatrogenic harm to present its activism as harm reduction, while objectively conspiring to produce Prohibition 2.0 through distributed anxiogenesis. Psymposia received over $400,000 in funding, mostly from undisclosed sources, some likely used for communications consultancy and media access. The authors reject the group's position as incoherent and damaging to substantive Left politics, arguing its exaggerated influence reflects unusual conditions of knowledge production in psychedelic spaces and the online attentional economy.
Study at a glance
| Design | theoretical or philosophical paper |
|---|---|
| Key finding | Psymposia's sensationalist activism against MDMA therapy functioned as an entrepreneurship of psychedelic negativity that objectively promoted Prohibition 2.0, despite being presented as harm reduction. |
Abstract
This article outlines a skeptical appraisal of Psymposia, a small but influential self-appointed psychedelics “watchdog” organization based in the United States of America, which played a significant role in blocking regulatory approval for MDMA as a treatment for PTSD in 2024. Contextualized close analysis of its “Power Trip” podcast series, which focused on sexual abuse in the psychedelic community, interventions by its members during the FDA hearings and its allegations regarding a “Psychedelic Syndicate,” shows the group to have been an effective entrepreneur of psychedelic negativity. This article questions the group's sensationalist approach to trauma and the excessively narrow understanding of iatrogenic harm within which it presents its activism as harm-reduction, arguing that its opportunistic interventions have been conspiring objectively to produce Prohibition 2.0 by distributed anxiogenesis. Our research also shows that the group has benefited from over $400,000 USD in funding, most of it from undisclosed sources, some of which was likely used to fund “Comms” consultancy and buy media access. In conclusion, we reject the group's overall position and strategy as incoherent yet objectively damaging to substantive Left politics. The group's exaggerated influence is a reflection of the unusual conditions of knowledge production in psychedelic spaces over the last decade, especially in the online attentional economy. By naming the entrepreneurship of psychedelic negativity and by reflecting on the scope of iatrogenic harm and the meaning of harm reduction, this article aims to bring balance to ongoing cultural conversations around the medicalization of psychedelics, decriminalization, and the potential in these substances to catalyze socio-political transformation from the Left.